Search page

A 12 months real-life prospective study of lung function in patients with severe eosinophilic asthma undergoing therapy with ics/laba, lama, and anti IL5/5R monoclonal antibody

A Regulatory Risk haplotype in HLA-DQ region regulates antigen presentation of monocyte in Type 2 inflammation in chronic rhinosinusitis with nasal polyps

A novel approach of pooling donors for basophil testing to diagnose type 2 autoimmune chronic spontaneous urticaria

A proof-of-concept study on an artificial intelligence model for biological therapy decision-making in severe asthma

Adverse reactions to biologicals in severe asthma

Allergen immunotherapy in patients with allergic rhinitis and asthma associated with reduced risk of severe COVID-19

Allergy and Asthma – Session 1: Diagnosing Asthma

Allergy and Asthma – Session 2: Precision medicine in pediatric asthma

An interim analysis of a multi-center, oPEn label, Randomized study to investigate the saFEty of an optimal acCelerated scheme for immunoTherapy in adolescent and adult patients with moderate to severe AR with or without asthma in China. (PERFECT)

Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years

Artificial intelligence-based B-cell epitope peptide immunotherapy alleviates chitin-binding protein-induced type 2 airway inflammation in Blomia tropicalis

Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

Assessing the Impact of Dupilumab Treatment on Lung Function in Patients With Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Association of asthma severity with high sensitivity C-reactive protein (hsCRP) in the all-age asthma cohort ALLIANCE

Asthma 2

Asthma Severity and Patient-Reported Outcomes in Patients With Asthma and Allergic Rhinitis Initiating Dupilumab in RAPID

AstraZeneca – Transforming severe asthma respiratory care: the clinical experience

Baseline Characteristics of Patients with Severe Asthma in Spain according to biological treatment use: BREATHE study

Baseline disease burden in severe asthma patients treated with biologics, and eligible but not treated: Spanish patients in the ISAR Registry

Benefits of the combination of biologics in the control of a patient with high type 2 profile: a case report

Benralizumab effectiveness in severe eosinophilic asthma patients from Central Eastern Europe and Baltics: BREEZE study

Benralizumab reduces annual cumulative OCS dose while improving asthma control and quality of life in severe eosinophilic asthma: Real-World Evidence from the AURORA study

Biomarkers shaping severe asthma phenotypes

Cannabinoid agonist WIN55,212-2 improves bronchial epithelial barrier alterations in the context of viral infection and type 2 inflammation

Case Report: Management of Severe Asthma and Multiple Food Allergies with Omalizumab. Outcomes Following an 18-Month Step-Down Therapy

Causes of death in patients diagnosed with severe asthma in our area- 10 years observational study

Characteristics of Patients with Uncontrolled Severe Asthma Undergoing Biological Therapy Based on Spirometric Response: Our Experience

Characteristics of patients with severe asthma undergoing biological treatment at a reference center

Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: Findings from the European CRS Outcome Registry (CHRINOSOR)

Clinical Characteristics of Patients with Severe Asthma by Different Elevated Biomarkers Classifications: Patients from Spain in the ISAR Registry

Clinical effects of dupilumab in patients with rhinosinusitis, nasal polyposis, and severe uncontrolled asthma with t2 phenotype, after 12 months of treatment

Clinical implications of biologic therapies in comorbid severe asthma and CRSwNP

Clinical profile of 457 Latin-American severe asthma patients in Mexico: differences between those who are and those who are not on biologics (OMA, DUPI, anti-IL5)

Comprehensive Analysis Of Pediatric ICU Admissions For Severe Acute Asthma Over A Decade

Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Cytometric detection of Der p 1 and Der p 2 binding to Basophils (CytoBas) enables precise determination of house dust mite sensitization in patients with asthma and allergic rhinitis

Dietary fructo-oligosaccharides induced suppression of type 2 inflammation coincides with changes in the fecal microbiome and local and systemic short chain fatty acids levels in a mouse model for house-dust-mite allergy

Disease Burden of Severe Asthma Patients Treated with Medium and High Doses of ICS: A Regional Database Analysis from China

Distribution of Baseline Type 2 Inflammation Characteristics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Biologic Clinical Trials: A Comparative Assessment

Distribution of IL-1β Expression in Asthma Patients and Comparison of Therapeutic Efficacy of Different Administration Routes of IL-1β Neutralizing Antibody in a Mouse Model of Asthma

Does severe asthma exist in preschool children?

Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)

Dupilumab Improves Type 2 Inflammatory Biomarkers Over Time in Patients With Chronic Obstructive Pulmonary Disease

Dupilumab Reduces FeNO levels and Exacerbations and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis

Dupilumab as a New Therapeutical Approach in Patients with Severe Seasonal Asthma Caused by Olive Pollen Sensitization

Dupilumab treatment effectively reduces nasal type 2 cytokine production following acetylsalicylic acid provocation in N-ERD patients

Dupilumab-Induced Diffuse Eosinophilic Drug Rash with Hypereosinophilia in a Patient with Idiopathic Pulmonary Fibrosis and Severe Asthma Exacerbation: A First Case Report

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

Dupilumab-induced skin reaction in a patient with severe asthma and chronic rhinosinusitis with nasal polyposis and without prior skin conditions

Early Real-World Outcomes of Tezepelumab in Severe Asthma Patients Unresponsive to Prior Biologics

Effect of baseline long-acting muscarinic antagonist (LAMA) use on inhaled corticosteroid dose reduction in patients with severe eosinophilic asthma treated with benralizumab: SHAMAL post-hoc analysis

Effectiveness of Dupilumab in improving Quality of Life in patients with “steroid-resistant” asthma and severe atopic dermatitis

Effectiveness of allergy immunotherapy on asthma medication use and asthma exacerbations: Results from the Real world Evidence of aLlergy immunotherapY (RELY) study

Efficacy and Safety of Dupilumab in Children Aged 6 Months to 5 Years With Atopic Dermatitis With and Without Type 2 Comorbidities

Efficacy of Dupilumab in patients over 50 years of age with severe asthma

Efficacy of Rilzabrutinib on Asthma Control: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Efficacy of Rilzabrutinib on Asthma Quality of Life: Results From a Double-Blind Placebo-Controlled Phase 2 Study

Elevating patient treatment outcomes in Severe Asthma

Elevating patient treatment outcomes in Severe Asthma & comorbid CRSwNP

Emerging therapies and approaches for achieving remission in severe asthma

Eosinophil-derived neurotoxin measured in nasal mucosal lining fluid (Nasosorption) is a promising type 2 biomarker in allergic rhinitis

Eosinophilic Esophagitis and Atopy: A Shared Mechanism of Type 2 Inflammation

Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients With Uncontrolled Moderate-to-Severe Asthma: The VESTIGE Trial

Evaluation of remission of Severe Asthma treated with monoclonal antibodies according to different definitions: a single center cohort

Evaluation of the Pediatric Patients with Severe Eosinophilic Asthma Treated with Mepolizumab

Expansion of allergen-specific type 2 memory B cells with an altered phenotype after immunotherapy for bee venom or ryegrass pollen allergy

Exploring the relationship between 6 minutes walk test (6MWT) performance and lung function in Severe Asthma and CRSwNP

First clinical practice of using biologic therapy with dupilumab in combination with allergen-specific immunotherapy in a patient with severe atopic dermatitis and bronchial asthma

From adults to children: Translating severe asthma research to pediatrics

GSK – Elevating patient treatment outcomes in severe asthma and CRSwNP

How can we unravel the type 2 low mechanism

ICS use trajectories in severe asthma patients on benralizumab: real-life data from 3-years follow-up

Identification of candidate biomarkers for diagnosing and assessing the disease severity of type 2 hereditary angioedema via plasma N-glycomics

Immunodeficiency spectrum in patients with severe asthma receiving biologicals

Immunostimulatory or immunosuppressive role of type 2 innate lymphoid cells

Impact of Immunogenicity on Clinical Outcomes in Patients from a Severe Asthma Unit Treated with Mepolizumab

Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers

Impact of asthma on severe food-induced allergic reactions: a systematic review and meta-analysis

Impact of overweight and obesity on clinical remission and Response to Biologics in Severe Asthma Patients

Improving severe asthma through psychological management of traumatic life events

Infective asthma exacerbations in severe asthmatic patients receiving biological drugs

Inflammatory phenotypes of severe asthma from sputum and plasma proteomic profiles

Insights from the BREATHE Study: Comorbidity Burden and Biomarker Trends in Severe Asthma Patients

Involvement of Janus kinase (JAK)-dependent Bcl-xL overexpression in steroid resistance of group 2 innate lymphoid cells (ILC2s) in asthma

Is remission an adequate therapeutic goal for severe asthma

LPS presence promotes, but is not required for, an ovalbumin induced type 2 mucosal immune response in vitro

Lichen Planus induced by treatment of severe eosinophilic asthma with biological therapy

Lichen planus following dupilumab treatment in patients with severe asthma and nasal sinus polyposis

Long-Term Efficacy of Mepolizumab at 5 Years in Patients with Severe Asthma

Managing patients with Type 2 inflammation in a joint interdisciplinary “United Airways Clinic” at Lund University Hospital, Sweden

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma, Independent of Baseline IgE and FeNO in the Real World: 2-Year Results from REALITI-A

Mepolizumab as game changer in a case of severe occupational asthma with rhinitis and contact dermatitis

Mepolizumab simultaneously improves clinical outcomes in severe CRSwNP and asthma in the SYNAPSE study: Focus on global airway disease

Mid-Term Impact of Non-Pharmaceutical Interventions on the Epidemiology of Hospitalizations for Severe Asthma Exacerbation in Children : A Time-Series Analysis

Modulation of allergen-specific type 2 memory B cells over the course of 18 months sublingual immunotherapy for house dust mite allergy

Molecular allergen sensitizations drive phenotypes of severe asthma in children: evidence from a megacity cohort (SAMP)

Monitoring Patients with Severe Eosinophilic Asthma Receiving Benralizumab in Allergy Centers in Greece for 8-12 months – REALISM-A Study (gReek rEAl Life regIStry of benralizuMab among Allergists)

New strategies in the treatment of severe asthma

Novel roles of type 2 innate lymphoid cells in allergic diseases

Omalizumab Combined Chinese Traditional Medicine in a Complicated Severe Asthma after Bronchial Thermoplasty

Outcomes in chronic rhinosinusitis and type 2 inflammation

OverSEA: European Delphi Consensus Study on Best Practices for patients with Severe Eosinophilic Asthma and comorbid CRSwNP

PTGDR2 Blood Expression as a Potential Biomarker for Predicting Super-Response to IL-5-Targeted Therapies in Severe Asthma

Patients with severe eosinophilic asthma starting anti-IL5 treatment after 2018 have better preserved lung function compared to the patients who started treatment earlier

Pediatric problematic severe asthma

Predictors of biological therapy in severe asthma patients. An ambispective study from the BIOBADALER consortium

Predominance of eosinophilic pathogenetic mechanisms in a severe allergic asthma patient on biologic therapy

Pro-inflammatory cytokines (IL-6 and TNF), influence of the JAK-STAT cascade and negative regulation of the Hyppo pathway in the severe asthma phenotype

Progression of Underlying Disease in Pediatric Severe Asthma

Progressive increase of the intervals between omalizumab administration in severe asthma

Real-life data analysis of severe asthma patients undergoing biologic therapy: OCS consumption and respiratory function evaluation

Real-life experience with tezepelumab in severe allergic asthma

Real-world effectiveness of dupilumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is independent of comorbidities, sinus surgery history and level of type 2 inflammation: Findings from CHRINOSOR

Regulation of the type 2 imprint by microbes and environmental factors

Relevance of IL-17-associated immune pathways and CXCL10 expression in severe childhood asthma

Retrospective analysis of quantitative CT characteristics of patients with severe asthma treated with biological agents: KoSAR registry

SLC27A2 marks lipid peroxidation in nasal epithelial cells driven by type 2 inflammation in chronic rhinosinusitis with nasal polyps

Selection of Biologics for Severe Pediatric Asthma with Allergic Eosinophilic Phenotype

Serum Levels of Cytokine in Individuals with Severe Asthma with Obesity

Serum cytokine profiles of pediatric normal weight asthma and overweight/obese asthma and their correlation with pulmonary function indices

Severe Asthma and Depression: the Overlooked Burden

Severe Asthma and Obesity: A retrospective study

Severe Bronchial Asthma Phenotypes in a Referral Tertiary Center in Saudi Arabia

Severe Eosinophilic Asthma later recognized as EGPA treated with Benralizumab

Severe asthma in pediatrics and Dupilumab after failure with Omalizumab

Severe asthma or COPD with eosinophilic inflammation? – from uncertainty to remission under anti-IL-5R therapy

Stability of steroid-dependent severe asthma during 5-year follow-up

Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria

Successful treatment of severe asthma after switch of biologics. A case report

Successfully managing severe asthma

Sustained reduction in Severe Asthma Exacerbations and Hospitalisations in the 12 months after Alpine Altitude Climate Treatment

T2 inflammatory profile of 457 Latin-American severe asthma patients in Mexico: differences between those who are and those who are not on biologics (OMA, DUPI, anti-IL5)

Targeted Metabolomic Profiling as a Tool for Assessing Response to Biologicals: a case of Dupilumab in Severe Allergic Asthma

Targeted therapies in pediatric severe asthma

Targeting TSLP in severe asthma

Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study

The Fundamental Role of Education in Achieving Control in a Child with Severe Uncontrolled Asthma

The Hidden Costs of Severe Asthma Treatment: Unveiling the Iatrogenic Burden

The Influence of Dupilumab on the Nasal and Gastrointestinal Microbiome in Diffuse Type 2 Chronic Rhinosinusitis

The impact of Type 2- targeted biological therapies on persistent cough in adults with cough variant- or cough predominant asthma

The modulation of ICAM-1 and ICAM-3 is mediated by alarmins in severe eosinophilic asthma

The relevance of IL-5 biology in severe asthma

The role allergic sensitization in severe asthma

Toward Optimal disease control: impact of maintenance inhaler therapy and device transition in severe asthma patients undergoing monoclonal antibody treatment

Transforming severe asthma respiratory care: the clinical experience

Treatment of severe asthma (update)

Type 2 Responses and the Future of Food Allergy Treatment: A Biological Perspective

Type 2 immunity at the mucosal barriers

Type 2 innate lymphoid cells in cancer immunity.

Type 2 responses in the lungs: mechanisms and implications

Use of biologics in severe uncontrolled asthma at National Institute of Pediatrics 2020-2023

Variables predicting clinical remission among adults with severe asthma treated with biologic agents

Worse asthma control in patients with asthma and respiratory allergies in the CAPTURE study: Rationale for developing the RespiratoryAllergyOptimiser

“Can Do, Do Do“ in patients with severe uncontrolled asthma referred for pulmonary rehabilitation in the alpine climate

Asthma control, lung function, and quality of life in pediatric patients with severe asthma undergoing biological treatment

Biologics have Solved the Problem of Type 2 Asthma

Characteristics of asthma phenotypes: Does coexistence of allergic and eosinophilic asthma increase asthma severity?

Characteristics of severe eosinophilic asthma in childhood-onset and adult-onset asthma in U-BIOPRED

Comparison of the proteomic profile in tears between patients with severe atopic dermatitis and severe asthma treated with Dupilumab

Decoding Asthma Therapies: Transcriptomic differences between benralizumab and mepolizumab treatment in patients with severe eosinophilic asthma

Dietary intervention with fructo-oligosaccharides in a mouse-model for house dust mite allergy enhances type 1, while lowering HDM specific type 2 responses in the lungs

Dissecting the molecular mechanisms underlying TSLP-driven non-type 2 inflammatory responses in severe asthma

Dupilumab Reduces Seasonal Exacerbation Rates in Children With Type 2 Asthma With or Without Evidence of Allergy

Dupilumab: Real-Life Effectiveness, Safety, and Impact on Type 2 and Non-Type 2 Comorbidities in Atopic Dermatitis Across Paediatric, Adolescent, and Adult Patients in Argentina – A 5-Year Review

Effectiveness of Tezepelumab in uncontrolled severe asthma. ADVANCAT (Advancing severe asthma care with Tezepelumab in Catalonia)

Effects of dupilumab on quality of life and airflow obstruction in refractory type 2 high severe unified airways disease

Evaluation of Asthma Course in Patients Hospitalized in Pediatric Intensive Care Unit Due to Severe Asthma Exacerbation

Evaluation of the concordance of definitions of Asthma Remission according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma

Hereditary α-Tryptasemia in Severe Allergic Asthma: Impaired Lung Function, Reduced Type 2 Biomarkers, and Suboptimal Omalizumab Response

Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Increase in airway resistance and respiratory bronchial reactivity is accompanied by cellular and antibody Type 2 immune response in a mouse model of asthma induced by Der p 23 allergen

Inhaled Corticosteroid Reduction Effects on Asthma Outcomes after Three Years of Benralizumab Treatment in Severe Asthma Patients

Lung Function Improvement is Associated With Better Asthma Control in Adolescents and Adults Aged 12 Years and Older With Moderate-to-Severe Type 2 Asthma: A Post Hoc Analysis of QUEST

Lung Function Responder Rates in the VOYAGE study in Children with Moderate-to-Severe Type 2 Asthma Receiving Dupilumab at Week 52

Lung function and exacerbations by different type 2 inflammation criteria in a general asthma population

Prevalence of severe fatigue and its contributing factors in patients with severe asthma

Real-world effectiveness of biologics in patients with severe asthma: analysis of the Korean Severe Asthma Registry (KoSAR)

Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma

Registry on Severe Asthma with and without biological treatment in Spain: Results of a 2 year follow-up of AlergoDATA

Severe asthma associated with hereditary angioedema type 1 and other pathologies

The effect of therapies targeting Type 2 inflammation on Neutrophil Extracellular Traps (NETs) and Extracellular Eosinophilic Traps (EETs) in severe CRSwNP

The m6A demethylase FTO mediates type 2 inflammation in asthma by regulating STAT6 mRNA stability

The relationship between asthma duration and biomarker profiles in severe asthma

The triple type 2 signature is associated to asthma severity and comorbidity with CRS

Type 2-high airway inflammation in childhood asthma distinguishes a more severe phenotype

Characteristics of Severe type 2 Asthma Patients in China: A Retrospective Observational Study

Dupilumab Reduces Exacerbations and Improves Asthma Control in Children With Moderate-to-Severe Type 2 Asthma, Regardless of Asthma Duration

Indirect case matched comparison of dupilumab versus benralizumab on mannitol airway hyperresponsiveness in type 2 high severe asthma

Mepolizumab Improves and Sustains Asthma Control and Lung Function in Patients with Severe Asthma Independent of Baseline Blood Eosinophil Count in the Real World: Results from REALITI-A at 2 Years

Real-world change in asthma symptom control and oral corticosteroid use in patients with severe asthma treated with mepolizumab stratified by atopic status: Post hoc analysis of REALITI-A at 2 years

Severe asthma and sleep disorders: a Severe Asthma Network Italy (SANI) analysis

Characteristics and Asthma Control Status of Severe Asthma Patients in the Korean Severe Asthma Registry-2 (KoSAR-2)

Welcome

Only match titles

What are you looking for?

Knowledge Hub

Website

Only match titles

What are you looking for?

Knowledge Hub

Sponsored Symposia

Event Resources

Covid-19

Courses

Guidelines

Position Papers

Website

Sessions